Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CC-94676 + Degarelix |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CC-94676 | CC94676|CC 94676|AR Degrader CC-94676|BMS-986365|BMS986365 | Hormone - Anti-androgens 58 | CC-94676 is a ligand-directed degrader of AR that potentially decreases Ar signaling and tumor growth (Cancer Res (2024) 84 (7_Supplement): ND02). | |
| Degarelix | Firmagon | FE200486 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07335796 | Phase II | CC-94676 + Degarelix | A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer | Recruiting | USA | 0 |